Laurus Labs Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - The company stated a philosophy of investing in capex if opportunities arise but did not indicate any planned fundraising. - They mentioned an ongoing gradual deleveraging strategy following improved operating performance, implying no immediate need for additional debt. - There is a strategic investment by Eight Roads into the biotech arm, but this appears to be an existing partnership rather than a new fundraising round. - The company plans to invest around INR40 crores before June 2025 in the Bio segment alongside partners but did not specify this as new fundraising. - Overall, no direct announcements or plans for raising new debt or equity were disclosed during the call.

- Laurus Labs opened a new R&D center last quarter, equal in size to the current R&D, to handle more molecules and early-stage programs. Further augmentation of scientific talent is planned for more clinical programs. - Capex philosophy: Investment will continue if opportunities arise; no fixed reduction plan. - Investing around INR120 crores in a CGT (cell and gene therapy) GMP facility expected in FY '26, catering to viral vectors and plasmid manufacture. - Two large-scale bio capacity facilities under construction: one in Vizag (operational by end of 2026) and another in Mysore. - A 400 KL fermentation capacity being created mainly for internal use, not for partners. - Strategic investment by Eight Roads in the biotech arm; Laurus and partners to invest additional INR40-35 crores by June 2025. - Capex of INR3,000 crores since FY '22, with about half yet to be commercialized; further capex will be over and above this.

- CDMO division expects continued robust growth in FY '26 and beyond, with a well-diversified pipeline of late-stage clinical programs. - No specific quantification for FY '26 sales, but prospects in CDMO are very bright with anticipated substantial growth over FY '25. - Formulation and API businesses expected to see significant medium-term growth, possibly starting FY '27, as the pipeline broadens. - Bio division growth expected to be limited in FY '26 due to capacity debottlenecking but anticipated to see big growth from FY '27 onwards. - Animal health and CropScience segments to experience significant growth next year. - The GMP gene therapy viral vector manufacturing facility to start contributing commercially from FY '26. - ARV franchise revenues expected to stabilize around INR 2,300-2,500 crores per annum. - Capex investments will continue as per opportunities to support growth.

- Laurus Labs expects continued growth in their CDMO business, with FY '26 anticipated to be better than FY '25, though exact revenue or margin guidance is not provided. - The Bio division is expected to show significant growth starting FY '27, after capacity expansions complete by end of 2026; FY '26 is likely to see minimal growth. - Formulation and API segments are not expected to see quantum jumps in FY '26 but are projected to grow significantly in the medium term, possibly from FY '27 onward. - The company's EBITDA margin target for the full financial year remains close to 20%, with progressive improvement expected in Q4. - Growth from multiple products and diversification in the CDMO segment is expected to provide sustainable revenue streams. - No explicit EPS or profit figures are provided, but the management expresses confidence in value creation and improved operating leverage going forward.

- The company has a robust pipeline with multiple ongoing projects in the CDMO division, including more than 70 projects featuring breakthrough designated molecules. - CDMO division recorded its highest quarterly sales in the last 8 quarters, close to INR 400 crores, with a 33% growth over 9 months, indicating strong demand and order flow. - Multiple commercial launch quantities and registration batches were supplied in Q3 and Q4 for several products, showcasing diversified and growing orderbook. - The company continues to receive encouraging RFPs (Request for Proposals) and is signing early to mid-stage projects involving complex chemistry. - Augmentation of R&D and scientific talent is being done to handle more clinical programs and pipelines. - Capex investments continue to be made opportunistically to support growth projects and new facility capacities. - Overall, the management expresses confidence in sustainable growth backed by a well-diversified and increasing project pipeline.